These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 21383005)
1. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005 [TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus. Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298 [TBL] [Abstract][Full Text] [Related]
3. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. Bai J; Chen J; Ma M; Cai M; Xu F; Wang G; Tao K; Shuai X DNA Cell Biol; 2014 Jun; 33(6):337-44. PubMed ID: 24588771 [TBL] [Abstract][Full Text] [Related]
4. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis. Chen Y; Pan K; Wang P; Cao Z; Wang W; Wang S; Hu N; Xue J; Li H; Jiang W; Li G; Zhang X J Biol Chem; 2016 Jun; 291(24):12688-12705. PubMed ID: 27129219 [TBL] [Abstract][Full Text] [Related]
5. Expression of polycomb group protein EZH2 in nevi and melanoma. McHugh JB; Fullen DR; Ma L; Kleer CG; Su LD J Cutan Pathol; 2007 Aug; 34(8):597-600. PubMed ID: 17640228 [TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841 [TBL] [Abstract][Full Text] [Related]
7. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. So AY; Jung JW; Lee S; Kim HS; Kang KS PLoS One; 2011 May; 6(5):e19503. PubMed ID: 21572997 [TBL] [Abstract][Full Text] [Related]
10. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells. Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937 [TBL] [Abstract][Full Text] [Related]
11. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480 [No Abstract] [Full Text] [Related]
12. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929 [TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120 [TBL] [Abstract][Full Text] [Related]
15. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Balasubramanian S; Adhikary G; Eckert RL Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867 [TBL] [Abstract][Full Text] [Related]
16. Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence. Huang JM; Chikeka I; Hornyak TJ Dermatol Clin; 2017 Jan; 35(1):85-93. PubMed ID: 27890240 [TBL] [Abstract][Full Text] [Related]
17. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278 [TBL] [Abstract][Full Text] [Related]
18. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Karanikolas BD; Figueiredo ML; Wu L Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877 [TBL] [Abstract][Full Text] [Related]
19. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431 [TBL] [Abstract][Full Text] [Related]
20. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells. Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]